prednisone has been researched along with bortezomib in 203 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 41 (20.20) | 29.6817 |
| 2010's | 129 (63.55) | 24.3611 |
| 2020's | 33 (16.26) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jäger, U | 1 |
| Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Heule, F; Lam, K; Sonneveld, P; Wu, KL | 1 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Fassas, AB; Tricot, G | 1 |
| Hatake, K; Terui, Y; Yokoyama, M | 1 |
| Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S | 1 |
| Ganser, A; Peest, D | 1 |
| Faiman, B | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS | 1 |
| Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W | 1 |
| Eom, HS; Huh, J; Kang, HJ; Kim, K; Kim, WS; Ko, YH; Lee, J; Park, K; Ryoo, BY; Suh, C | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Durie, BG | 1 |
| Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Cheson, BD | 1 |
| Ambrus, JL; Islam, A | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Avvisati, G | 1 |
| García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Berenson, JR | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G | 1 |
| Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H | 1 |
| Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM | 1 |
| Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G | 1 |
| Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Colby, TV; Fonseca, R; Khan, ML; Viggiano, RW | 1 |
| Everly, MJ; Jahr, F; Kaneku, H; Terasaki, PI; Trivedi, HL | 1 |
| Lonial, S | 1 |
| Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H | 1 |
| Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Rajkumar, SV | 2 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D | 1 |
| Palumbo, A | 1 |
| Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K | 1 |
| Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM | 1 |
| Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Schots, R | 1 |
| Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J | 1 |
| Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O | 1 |
| Brandt, S; Chinratanalab, W; Englehardt, B; Goodman, S; Greer, JP; Jagasia, MH; Kassim, A; Morgan, DS; Oluwole, O; Reddy, N; Savani, BN | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M | 1 |
| Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI | 1 |
| Harousseau, JL | 1 |
| Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Lonial, S; Miguel, JF | 1 |
| Mina, R; Palumbo, A | 1 |
| Bagot, M; Bezier, M; Cordoliani, F; Delyon, J; Malphettes, M; Rybojad, M; Szalat, R | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Drach, J; Drach-Schauer, B; Eder, S; Lamm, W | 1 |
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI | 1 |
| Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J | 1 |
| Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK | 1 |
| Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| Tsurumi, H | 1 |
| Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A | 1 |
| Brown, RE; Nguyen, ND; Quesada, AE; Rios, A | 1 |
| Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H | 1 |
| Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES | 1 |
| Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J | 1 |
| Ishida, T | 1 |
| Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| AlAli, HK; Andrea, M; Becker, C; Edelmann, T; Franke, GN; Gutsche, K; Hammerschmidt, D; Heyn, S; Hoffmann, FA; Holzvogt, B; Jentzsch, M; Kreibich, U; Lange, T; Leiblein, S; Niederwieser, D; Plötze, M; Poenisch, W; Reifenrath, K; Schliwa, T; Schwarz, M; Schwarzbach, H; Schwarzer, A; Schwind, S; Vucinic, V; Zehrfeld, T | 1 |
| Dreyling, M | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Chaturvedi, S; Enny, C; Eom, HS; Ferhanoglu, B; Offner, F; Osmanov, E; Pavlov, V; Raposo, J; Ricci, D; Rizo, A; Samoilova, O; Topp, MS; van de Velde, H; Zhu, E | 1 |
| Bumpers, N; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; Koff, JL; Langston, AA; Lechowicz, MJ; Lonial, S; Nastoupil, LJ; Sinha, R; Switchenko, JM | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Bernstein, SH; Burack, WR; DaSilva, MA; Fisher, RI; Floyd, JD; Friedberg, JW; LeBlanc, M; Li, H; Moore, DF; Pozdnyakova, O; Rimsza, LM; Smith, SM; Till, BG | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Alexandrakis, MG; Antonakis, A; Devetzoglou, M; Kokonozaki, M; Kyriakaki, S; Pappa, CA; Tsirakis, G; Tzardi, M; Vyzoukaki, R | 1 |
| Hellmich, M; Kuhr, K; Lehmacher, W; Srivastava, K; Wirth, D | 1 |
| An, Z; Li, F; Song, P; Wang, L; Wang, X; Yu, Y; Zhai, Y; Zhao, Q; Zhou, X | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Fedele, PL; Gilbertson, M; Gregory, GP; Grigoriadis, G; Kumar, B; Opat, S; Shortt, J | 1 |
| Aghemo, E; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Carella, AM; Conticello, C; De Paoli, L; De Rosa, L; Derudas, D; Falcone, AP; Genuardi, M; Guglielmelli, T; Larocca, A; Liberati, AM; Montefusco, V; Morabito, F; Musolino, C; Nozzoli, C; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Petrucci, MT; Ponticelli, E; Sonneveld, P; Spada, S; Villani, O; Vincelli, ID | 1 |
| Abel, H; Ambinder, R; Barta, SK; Baydoun, HH; Caruso, B; Cheng, X; Harding, J; Jacobson, S; Noy, A; Parekh, S; Phillips, A; Ramos, JC; Ratner, L; Rauch, D | 1 |
| Akashi, K; Hiyamuta, H; Kitazono, T; Masutani, K; Matsukuma, Y; Muta, T; Nakano, T; Taniguchi, M; Tsuchimoto, A; Tsuruya, K; Yamada, S; Yoshimoto, G | 1 |
| Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Prica, A; Reece, DE; Tiedemann, R; Trieu, Y; Trudel, S | 1 |
| Gairy, K; Lee, D; Seshagiri, D; Thilakarathne, P; van Keep, M | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M | 1 |
| Boccadoro, M; Bringhen, S; Grammatico, S; Petrucci, MT; Siniscalchi, A; Vozella, F | 1 |
| Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS | 1 |
| Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS | 1 |
| Kobayashi, H; Miyagi, N | 1 |
| Collins, R; de Vos, S; DiBella, NJ; Esseltine, DL; Flinn, IW; Flowers, CR; Hajdenberg, J; Horodner, A; Kolevska, T; Kolibaba, KS; Leonard, JP; Mulligan, G; Neuwirth, R; Papish, SW; Park, J; Reeves, JA; Robles, R; Suryanarayan, K; Tabatabai, A; Tulpule, A; Venugopal, P | 1 |
| Arora, N; Gupta, A; Sadeghi, N | 1 |
| Ludwig, H; Zojer, N | 1 |
| Campbell, P; Carson, R; Cavo, M; Chiu, C; Cook, M; Crepaldi, A; Crist, W; Deraedt, W; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iosava, G; Jakubowiak, A; Kaplan, P; Knop, S; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Nguyen, H; Pour, L; Qi, M; San-Miguel, J; Shelekhova, T; Suzuki, K; Wang, J; Yoon, SS | 1 |
| Stirrups, R | 1 |
| Dittus, C; Ellsworth, S; Grover, N; Park, SI; Tan, X | 1 |
| Belch, A; Bosly, A; Bunworasate, U; Cavalli, F; Dascalescu, A; Drach, J; Farber, C; Huang, H; Masliak, Z; Novak, J; Pei, L; Robak, T; Rooney, B; Samoilova, O; van de Velde, H; Vilchevskaya, K; Zaucha, J | 1 |
| Baldini, F; Bibas, M; Cartron, G; Castillo, JJ; Cwynarski, K; Dierickx, D; Fedele, P; Gilbertson, M; Grigoriadis, G; Guerrero-Garcia, T; Lansigan, F; Linnik, Y; Mogollon, R; Navarro, JT; Ninkovic, S; Olszewski, AJ; Reagan, JL; Tchernonog, E; Tousseyn, T | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Chen, X; Fang, Z; Li, Z; Lin, Z; Luo, Y; Xu, B; Zhao, J; Zhou, Y | 1 |
| Till, BG | 1 |
| Rule, S | 1 |
| Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES | 1 |
| Ahmed, S; Barrans, S; Bentley, MA; Burton, C; Caddy, J; Care, MA; Chalkley, R; Cucco, F; Cummin, T; Davies, A; Du, MQ; Johnson, PWM; Kennedy, H; Maishman, T; Mamot, C; Schuh, A; Sha, C; Thompson, JS; Tooze, R; Uddin, R; van Hoppe, M; Westhead, DR; Worrillow, L | 1 |
| Choi, KS; Choi, YW; Kim, IY; Kim, MA; Kwon, MR; Lee, AR; Lee, DM; Lee, HI; Seo, MJ; Shim, MJ; Yoon, MJ | 1 |
| Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kebriaei, P; Lee, HC; Manasanch, EE; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, RD; Popat, U; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Syed, YY | 1 |
| Cho, SH; Jung, KS; Kim, Y; Shin, HJ | 1 |
| Abdul-Hay, M; Naymagon, L | 1 |
| Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R | 1 |
| Hashim, M; Heeg, B; Ouwens, M; Postma, M; Soikkeli, F | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Deraedt, W; Dimopoulos, MA; Goldschmidt, H; Hashim, M; He, J; Heeg, B; Hu, P; Lam, A; Mateos, MV; San-Miguel, J; Sonneveld, P | 1 |
| Bhutani, M; Usmani, SZ | 1 |
| Killock, D | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Gertz, M; Vaxman, I | 1 |
| Al-Quteimat, OM | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Dingeldein, G; Goldschmidt, H; Habermehl, C; Knauf, W; Kunz, C; Moehler, T; Raab, MS; Schlag, R; Terzer, T; Walter, S; Welslau, M | 1 |
| Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J | 1 |
| Hollingworth, S; Loke, C; McPherson, I; Mollee, P; Mutsando, H; Tomlinson, R; Walpole, E; Weston, H; Wong, P; Yue, M | 1 |
| Cavo, M; Dimopoulos, MA; Fernandez, M; Garcia, A; He, J; Heeg, B; Hungria, V; Lam, A; Machnicki, G; Martínez-Baños, DM; Mateos, MV | 1 |
| Abonour, R; Agarwal, A; Ailawadhi, S; Durie, BGM; Gasparetto, C; Hardin, JW; Jagannath, S; Kitali, A; Lee, HC; Narang, M; Omel, JL; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Carson, R; Chari, A; Delioukina, M; Hulin, C; Hungria, V; Iida, S; Karlin, L; Kosh, M; Magen, H; Maisnar, V; Masterson, T; McCarthy, H; Parasrampuria, DA; Perrot, A; Pour, L; Qi, M; Rodriguez-Otero, P; Sureda Balari, A; Suzuki, K; Touzeau, C; Yang, S | 1 |
| Andrea, M; Becker, C; Bill, M; Braunert, L; Edelmann, T; Franke, GN; Grimm, J; Hammerschmidt, D; Hoffmann, FA; Holzhey, T; Holzvogt, B; Holzvogt, M; Jentzsch, M; Platzbecker, U; Pönisch, W; Remane, Y; Scholz, M; Schönfelder-Fricke, U; Schwarz, M; Schwarzer, A; Schwind, S; Wang, SY; Zehrfeld, T | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Li, S; Liu, Q; Luo, X; Peng, L; Peng, Y; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Abella, E; Alcalá, M; Bustamante, G; Cejalvo, MJ; de la Rubia, J; Duro, R; García, A; García, R; Garzón, S; González, E; González, MS; González, Y; Jarque, I; López, R; Lostaunau, G; Martí, JM; Motlló, C; Pérez-Persona, E; Ramírez-Payer, Á; Sampol, A; Sarrà, J; Sastre, JL; Vázquez-Álvarez, J | 1 |
| Campbell, P; Cavo, M; Cook, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fastenau, J; Fujisaki, T; Garg, M; Gries, KS; Grosicki, S; Jakubowiak, A; Knop, S; Kudva, A; Liberati, AM; Losava, G; Lucio, P; Mateos, MV; Nagy, Z; Pour, L; San-Miguel, J; Shelekhova, T; Suzuki, K; Usenko, G; Wang, J; Wroblewski, S; Yoon, SS | 1 |
| Cao, YW; Cheng, S; Qian, Y; Wang, L; Xu, PP; Zhao, WL; Zheng, Z | 1 |
| Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M | 1 |
| Bladé, J; Campbell, P; Cavo, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iida, S; Iosava, G; Knop, S; Kudva, A; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Pei, H; Pour, L; Qi, M; San-Miguel, J; Suzuki, K; Ukropec, J; Van Rampelbergh, R; Yoon, SS | 1 |
| Castillo, JJ; Flynn, CA; LaMacchia, J; Pozdnyakova, O; Sarosiek, S; Treon, SP | 1 |
| Bittner, A; Bogner, C; Bullinger, L; Denker, S; Dürig, J; Frick, M; Hoffmann, J; Hüttmann, A; Janz, M; Kase, J; Keller, U; Krohn, U; Marks, R; Mathas, S; Na, IK; Schmitt, CA; Trenker, C | 1 |
| Deng, J; Gong, Y; Liu, X; Wu, X; Ye, W; Zheng, X | 1 |
| Cuevas-Palomares, L; de Miguel-Sánchez, C; Díez-Angulo, R; Gabilondo-Jalón, M; Guinea de Castro, JM; Herraez, S; Menchaca, C; Mendizabal-Abad, A; Oiartzabal-Ormategui, I; Pérez-Persona, E; Pisón-Herrero, C; Robles-Castro, D; Salcedo-Cuesta, L; Santamaría-López, A; Unamunzaga-Cilaurren, A; Vega González-Viñaspre, A | 1 |
| Egea Valenzuela, J; Leal Rubio, JD; Mesa López, MJ; Muñoz Tornero, M; Salazar Nicolás, A | 1 |
| Aouba, A; Audemard-Verger, A; Battistella, M; Bigot, A; Brihaye, B; Cook, AR; Deriaz, S; Diot, E; El Karoui, K; Ferreira-Maldent, N; Hankard, A; Henique, H; Ingen-Housz-Oro, S; Jobard, S; Lioger, B; Magnant, J; Maillot, F; Paule, R | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Fukushima, N; Iida, S; Imaizumi, Y; Kagami, Y; Kameoka, Y; Kataoka, T; Katsuya, H; Kobayashi, M; Kobayashi, T; Kubota, N; Kurosawa, M; Machida, R; Maruta, M; Maruyama, D; Morimoto, H; Nagai, H; Ohba, R; Omachi, K; Sunami, K; Suzuki, T; Tabayashi, T; Takayama, N; Tokunaga, M; Yamamoto, K; Yoshida, I | 1 |
| Barrans, S; Burton, C; Caddy, J; Collins, GP; Cucco, F; Davies, AJ; Davies, JR; Du, MQ; Fields, P; Griffiths, G; Johnson, PWM; Mamot, C; McMillan, A; Novak, U; Saunders, G; Schuh, A; Sha, C; Stanton, L; Stephens, R; Tooze, R; van Hoppe, M; Westhead, DR; Wilding, S | 1 |
| Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA | 1 |
33 review(s) available for prednisone and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
[Recent progress in rituximab therapy and its resistance--how do we overcome?].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
[Current treatment of follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Prednisone; Prognosis; Pyrazines; Radioimmunotherapy; Radiotherapy, Adjuvant; Risk Factors; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Germany; Humans; Melphalan; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Thalidomide | 2016 |
Fixed duration vs continuous therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free Survival; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Rate; Thalidomide; Time Factors | 2017 |
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Peripheral Nervous System Diseases; Prednisone; Rituximab; Survival Rate; Vincristine | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Transplantation Conditioning | 2019 |
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
Topics: Aged; Bortezomib; Dexamethasone; Fatigue; Humans; Lymph Nodes; Lymphadenopathy; Male; Plasma Cells; Plasmacytoma; Prednisone; Remission Induction; Thalidomide | 2019 |
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Membrane Glycoproteins; Multiple Myeloma; Prednisone; Prognosis; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Signaling Lymphocytic Activation Molecule Family | 2021 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
64 trial(s) available for prednisone and bortezomib
| Article | Year |
|---|---|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2006 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome | 2007 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2008 |
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proteasome Endopeptidase Complex; Pyrazines; Vincristine | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome | 2010 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors | 2011 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2011 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant | 2011 |
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Cyclophosphamide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome | 2012 |
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine | 2012 |
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Prednisone; Pyrazines; Vincristine | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2012 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence | 2013 |
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome | 2013 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2014 |
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines | 2014 |
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2015 |
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2015 |
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Survival Rate; Vincristine | 2015 |
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prednisone; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Survival Analysis; Vincristine | 2016 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Survival Rate | 2016 |
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bortezomib; Child; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Rituximab; Survival Analysis; Vincristine; Young Adult | 2016 |
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Prednisone; Quality-Adjusted Life Years; Rituximab; United Kingdom; Vincristine | 2016 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone | 2017 |
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Vincristine; Young Adult | 2017 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate | 2018 |
Daratumumab for untreated multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Confidence Intervals; Disease-Free Survival; Female; Hospitals, University; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Spain; Survival Analysis | 2018 |
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized
Topics: Adult; Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Practice Guidelines as Topic; Prednisone; Progression-Free Survival; Rituximab; Stem Cell Transplantation; Thrombocytopenia; Treatment Outcome; Vincristine | 2018 |
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Survival Rate; Vincristine | 2019 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Progression-Free Survival; Renal Insufficiency; Treatment Outcome | 2020 |
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Propensity Score; Treatment Outcome | 2020 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Latin America; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Propensity Score; Retrospective Studies; Standard of Care | 2020 |
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Patient Reported Outcome Measures; Prednisone; Quality of Life; Treatment Outcome | 2021 |
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2023 |
106 other study(ies) available for prednisone and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine | 2003 |
Skin lesions induced by bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy | 2005 |
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; Glucocorticoids; Histamine H1 Antagonists; Humans; Male; Medical Records; Middle Aged; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Skin; Skin Ulcer | 2006 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine | 2008 |
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines | 2008 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
New evidence in oncologic and cardiocirculatory medicine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine | 2008 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
Successful bortezomib-based treatment in POEMS syndrome.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Treatment with bortezomib of a patient having hyper IgG4 disease.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Eyelid Diseases; Female; Humans; Immune System Diseases; Immunoglobulin G; Middle Aged; Plasma Cell Granuloma, Pulmonary; Prednisone; Pyrazines; Tomography, X-Ray Computed | 2010 |
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol.
Topics: Adrenal Cortex Hormones; Adult; Biopsy; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Follow-Up Studies; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; India; Kidney Transplantation; Living Donors; Prednisone; Protease Inhibitors; Pyrazines; Young Adult | 2009 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome | 2010 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
De novo AL amyloidosis in the kidney allograft.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protease Inhibitors; Pyrazines; Receptors, Neuropeptide; RNA, Messenger; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vincristine; Young Adult | 2011 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2012 |
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
[Cutaneous manifestations revealing cryofibrinogenaemia associated with monoclonal gammopathy].
Topics: Acute Kidney Injury; Adult; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cryoglobulinemia; Cryoglobulins; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fibrinogens, Abnormal; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Leg Ulcer; Microscopy, Fluorescence; Necrosis; Paraproteinemias; Plasmapheresis; Prednisone; Pyrazines; Skin | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult | 2013 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine | 2014 |
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines | 2015 |
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries | 2014 |
Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; NF-kappa B; Positron-Emission Tomography; Prednisone; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Vincristine | 2014 |
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Prednisone; Rituximab; Vincristine | 2014 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Blood Component Removal; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Rituximab; Standard of Care; Vincristine | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Endoglin; Female; Hepatocyte Growth Factor; Humans; Male; Melphalan; Membrane Proteins; Microvessels; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neovascularization, Pathologic; Prednisone; Receptors, Cell Surface; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Clinical Characteristics and Treatment Outcome of Chinese Patients With Systemic Amyloid Light-Chain Amyloidosis: A Retrospective Single-Center Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prednisone; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Infusions, Subcutaneous; Male; Plasmablastic Lymphoma; Prednisone; Treatment Outcome; Vincristine | 2016 |
Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Prednisone; Raltegravir Potassium; Treatment Outcome; Vincristine | 2016 |
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Liver Function Tests; Melphalan; Paraproteinemias; Prednisone; Treatment Outcome | 2016 |
Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Recurrence; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Autoantibodies; Bortezomib; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney; Lupus Nephritis; Male; Methylprednisolone; Prednisone; Proteinuria; Remission Induction | 2017 |
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bortezomib; Diarrhea; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Prednisone; Prospective Studies; Republic of Korea; Treatment Outcome | 2017 |
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; HIV Infections; Humans; Middle Aged; Plasmablastic Lymphoma; Prednisone; Remission Induction; Vincristine | 2017 |
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Induction Chemotherapy; Male; Plasmablastic Lymphoma; Prednisone; Vincristine | 2017 |
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Time Factors; Treatment Outcome; Vincristine | 2018 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Bortezomib-based chemotherapy in mantle cell lymphoma.
Topics: Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Rituximab; Vincristine | 2018 |
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Cyclophosphamide; Databases, Genetic; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Grading; Prednisone; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Transcriptome; Vincristine | 2019 |
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Death; Colonic Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; HCT116 Cells; HeLa Cells; Humans; Loperamide; Prednisone; Proteasome Inhibitors; Vincristine | 2019 |
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Plasmapheresis; POEMS Syndrome; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2019 |
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Republic of Korea; Survival Analysis; Treatment Outcome | 2019 |
Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Data Interpretation, Statistical; Decision Making; Female; Humans; Interatrial Block; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Quadruplets come of age for newly diagnosed multiple myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
ALCYONE - lighting the way for quadruplet therapy of NDMM.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
Non-transplant eligible multiple myeloma: deciphering optimal first line regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
Vincristine Shortage: What Other Options We Have?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Substitution; Humans; Leukemia; Liposomes; Lymphoma; Prednisone; Vinblastine; Vincristine; Vindesine | 2020 |
Bortezomib use and outcomes for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Queensland; Treatment Outcome | 2020 |
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Registries; Safety; Stem Cell Transplantation | 2021 |
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Standard of Care; Treatment Outcome | 2021 |
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Predictive Value of Tests; Prednisone; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Cost-Benefit Analysis; Humans; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years | 2021 |
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2021 |
[Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Prognosis; Rituximab; Vincristine | 2021 |
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Czech Republic; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Registries; Thalidomide; Treatment Outcome | 2021 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone | 2021 |
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clonal Evolution; Cyclophosphamide; Disease Progression; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lymph Nodes; Myeloid Differentiation Factor 88; Neoplasm Proteins; Piperidines; Plasmablastic Lymphoma; Prednisone; Protein Kinase Inhibitors; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Piperidines; Prednisone; Rituximab; Vincristine | 2022 |
Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2022 |
Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital.
Topics: Adult; Aged; Bortezomib; Dexamethasone; Diabetes Mellitus, Type 2; Female; Humans; Immunoglobulin G; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Prednisone; Rituximab; Tertiary Care Centers | 2022 |
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.
Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Retrospective Studies; Rituximab | 2022 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisolone; Prednisone; Prognosis; Treatment Outcome; United Kingdom | 2023 |
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Registries; Retrospective Studies; Treatment Outcome | 2023 |